Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Use of molecular markers to determine postremission treatment in acute myeloid leukemia with normal cytogenetics.

Hematology/oncology and stem cell therapy - 1 Dec 2015

Copelan Edward A, Grunwald Michael R, Druhan Lawrence J, Avalos Belinda R

Abstract excerpt

Most patients with acute myeloid leukemia can be induced into complete remission, but postremission treatment is required for cure. The choice of postremission therapy in a majority of nonelderly patients, between intensive chemotherapy and allogeneic hematopoietic cell transplantation, is largely determined by the results of conventional cytogenetic analysis. In 45% of patients with a normal karyotype, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Cytogenetic Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Karyotyping

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Remission Induction

Source

Identifiers

PMID: 26459077
DOI: 10.1016/j.hemonc.2015.09.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Use of molecular markers to determine postremission treatment in acute myeloid leukemia with normal cytogenetics.PMID 26459077Read ↗

Molecular markers in acute myeloid leukemia.Semantic proximity Read ↗

Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia.Semantic proximity Read ↗

Management of patients with cytogenetically normal acute myeloid leukemia who have neither favorable nor unfavorable markers.Semantic proximity Read ↗

Genetic Tests To Evaluate Prognosis and Predict Therapeutic Response in Acute Myeloid LeukemiaSemantic proximity Read ↗

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemiaSemantic proximity Read ↗

High cytogenetic or molecular genetic risk acute myeloid leukemia.Semantic proximity Read ↗

Molecular markers in acute myeloid leukaemiaSemantic proximity Read ↗

Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemiaSemantic proximity Read ↗

Diagnosis and relapse: cytogenetically normal acute myelogenous leukemia without FLT3-ITD or MLL-PTD.Semantic proximity Read ↗

Stopping Leukemia in Its Tracks: Should Preemptive Hematopoietic Stem-Cell Transplantation be Offered to Patients at Increased Genetic Risk for Acute Myeloid Leukemia?Semantic proximity Read ↗

Patient with chronic myeloid leukemia in complete cytogenetic response: what does it mean, and what does one do next?Semantic proximity Read ↗

Long-term haematological improvement after non-intensive or no chemotherapy in juvenile myelomonocytic leukaemia and poor correlation with adult myelodysplasia spliceosome-related mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.